MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

about

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic.The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis.

P2860

Q42372774-16676AA9-2909-488D-8BBF-E72AE3669B7C Q47658864-92FD078F-B478-41E7-BF69-27AFA723B47E Q49637506-11FA56BA-2BC5-412F-A10C-476209649287

P2860

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

Item

http://www.wikidata.org/entity/Q39266421

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

@en

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

@nl

type

Item

label

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

@en

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

@nl

prefLabel

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

@en

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

@nl

P1476

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

@en

P2093

Dessislava Marinova

http://www.w3.org/2001/XMLSchema#string

P2860

A new evolutionary scenario for the Mycobacterium tuberculosis complex

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

Genome plasticity of BCG and impact on vaccine efficacy

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

Evolutionary landscape of the Mycobacterium tuberculosis complex from the viewpoint of PhoPR: implications for virulence regulation and application to vaccine development

Updates on the risk factors for latent tuberculosis reactivation and their managements

Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data

Within Host Evolution Selects for a Dominant Genotype of Mycobacterium tuberculosis while T Cells Increase Pathogen Genetic Diversity

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP

P304

565-576

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14760584.2017.1324303

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nacho Aguilo

Carlos Martín

Jesús Gonzalo-Asensio

P577

2017-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28447476

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

about

P2860

P2860

MTBVAC from discovery to clinical trials in tuberculosis-endemic countries.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921